Nose-to-brain delivery of gold nanozyme with cascade effect for bacterial meningitis therapy

被引:0
|
作者
Deng, Shu-Yue [1 ]
Zhou, Xin-Yu [1 ]
Zou, Xiao-Peng [2 ]
Tang, Fang [3 ]
Yang, Dong [4 ]
Sun, Cai-Xia [1 ]
Luo, Jun [1 ]
Ge, Xing [1 ]
Zhu, Jia-Ying [1 ]
Fang, Tian-Ye [1 ]
Yue, Cai-Feng [2 ]
Ju, Yan-Min [1 ]
Dai, Jian-Jun [1 ,3 ]
机构
[1] China Pharmaceut Univ, Coll Pharm, Nanjing 211198, Peoples R China
[2] Guangdong Med Univ, Cent Peoples Hosp Zhanjiang, Zhanjiang Cent Hosp, Dept Lab Med, Zhanjiang 524045, Peoples R China
[3] Nanjing Agr Univ, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210095, Peoples R China
[4] Scripps Res Inst, Dept Neurosci, La Jolla, CA 92037 USA
来源
RARE METALS | 2025年
基金
中国国家自然科学基金;
关键词
Gold nanozyme; Bacterial meningitis; Nose-to-brain delivery; Bacterial resistance; NASAL DRUG-DELIVERY; PROGRESS; BARRIER;
D O I
10.1007/s12598-024-03132-7
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
The presence of the blood-brain barrier limits the drug concentration in the brain, while low concentrations of antibiotics make it difficult to kill infecting bacteria and tends to induce drug resistance, making the clinical treatment of bacterial meningitis challenging. Herein, a nose-to-brain delivery strategy of small-sized nanozyme has been fabricated for combating bacterial meningitis, to overcome the low drug concentration and drug resistance. This strategy was achieved by a protein-supported Au nanozyme (ANZ). With a particle size of less than 10 nm, it possesses both glucose oxidase-like and peroxidase-like activities and can generate large amounts of reactive oxygen species through a cascade effect without the addition of external H2O2. Benefiting from the cascade catalytic amplification effect generated by its dual enzyme-like activities, ANZ shows significant broad-spectrum antibacterial activity without inducing bacterial resistance in vitro. Notably, small-sized ANZ exhibits higher brain entry efficiency and greater accumulation after intranasal administration compared to oral or intravenous administration. In a mouse model of bacterial meningitis, the mice treated with ANZ had lower bacterial loads in the brain and higher survival and clinical behavior scores compared to the classical antibiotic ceftriaxone. Additionally, the meningitis mice exhibited undamaged cognitive and behavioral abilities, indicating the excellent biocompatibility of ANZ. The above results demonstrate that nose-to-brain delivery of ANZ exhibits high intracerebral accumulation, strong antibacterial efficacy and does not lead to bacterial resistance. It holds broad prospects for the treatment of bacterial meningitis. (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(ANZ), (sic)(sic)(sic)(sic)(sic)10(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)H2O2(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), ANZ(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).ANZ(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)ANZ(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), ANZ(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic), (sic)(sic)ANZ(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).(sic)(sic)(sic)(sic), ANZ(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic), (sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic)(sic).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Nose-to-Brain Delivery
    Wang, Zian
    Xiong, Guojun
    Tsang, Wai Chun
    Schatzlein, Andreas G.
    Uchegbu, Ijeoma F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (03): : 593 - 601
  • [2] Nose-to-Brain Delivery
    Giunchedi, Paolo
    Gavini, Elisabetta
    Bonferoni, Maria Cristina
    PHARMACEUTICS, 2020, 12 (02)
  • [3] Nose-to-brain delivery of tacrine
    Jogani, Viral V.
    Shah, Pranav J.
    Mishra, Pushpa
    Mishra, Anil Kumar
    Misra, Ambikanandan R.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (09) : 1199 - 1205
  • [4] Nanoparticles for Direct Nose-to-Brain Delivery of Gene Therapy
    Sanchez-Ramos, J.
    Song, S.
    Sava, V.
    NEUROTHERAPEUTICS, 2015, 12 (03) : 681 - 682
  • [5] Nose-to-brain delivery of biologics
    Schwarz, Bettina
    Merkel, Olivia M.
    THERAPEUTIC DELIVERY, 2019, 10 (04) : 207 - 210
  • [6] Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy
    Ferreira, Natalia Noronha
    Leite, Celisnolia Morais
    Moreno, Natalia Sanchez
    Miranda, Renata Rank
    Lins, Paula Maria Pincela
    Rodero, Camila Fernanda
    de Oliveira Junior, Edilson
    Lima, Eliana Martins
    Reis, Rui M.
    Zucolotto, Valtencir
    ACS APPLIED MATERIALS & INTERFACES, 2024, 17 (01) : 484 - 499
  • [7] Nanoemulsions for "Nose-to-Brain" Drug Delivery
    Bonferoni, Maria Cristina
    Rossi, Silvia
    Sandri, Giuseppina
    Ferrari, Franca
    Gavini, Elisabetta
    Rassu, Giovanna
    Giunchedi, Paolo
    PHARMACEUTICS, 2019, 11 (02):
  • [8] Nose-to-Brain Delivery of Antioxidants as a Potential Tool for the Therapy of Neurological Diseases
    Bonferoni, Maria Cristina
    Rassu, Giovanna
    Gavini, Elisabetta
    Sorrenti, Milena
    Catenacci, Laura
    Giunchedi, Paolo
    PHARMACEUTICS, 2020, 12 (12) : 1 - 21
  • [9] Nose-to-brain peptide delivery - The potential of nanotechnology
    Samaridou, Eleni
    Alonso, Maria Jose
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (10) : 2888 - 2905
  • [10] SLN approach for nose-to-brain delivery of alprazolam
    Alok Pratap Singh
    Shailendra K. Saraf
    Shubhini A. Saraf
    Drug Delivery and Translational Research, 2012, 2 : 498 - 507